

## PRIOR AUTHORIZATION POLICY

**POLICY:** Oncology (Injectable) – Poteligeo Prior Authorization Policy

- Poteligeo® (mogamulizumab-kpkc intravenous infusion – Kyowa Kirin)

**REVIEW DATE:** 09/04/2024

---

### OVERVIEW

Poteligeo, a CC chemokine receptor 4 (CCR4)-directed monoclonal antibody, is indicated for the treatment of relapsed or refractory **mycosis fungoides** or **Sézary syndrome** in adults after at least one prior systemic therapy.<sup>1</sup>

### GUIDELINES

Poteligeo is addressed in the National Comprehensive Cancer Network (NCCN) guidelines:

- **Primary Cutaneous Lymphomas:** Guidelines (version 3.2024 – August 22, 2024) recommend Poteligeo for primary treatment and for treatment of relapsed/refractory mycosis fungoides/Sezary syndrome.<sup>2,3</sup>
- **T-Cell Lymphomas:** Guidelines (version 4.2024 – May 28, 2024) recommend Poteligeo as a single agent for the second-line or subsequent treatment of relapsed/refractory adult T-cell leukemia/lymphoma; chronic high-risk, acute or lymphoma subtypes.<sup>3,4</sup>

### POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Poteligeo. All approvals are provided for the duration noted below. Because of the specialized skills required for evaluation and diagnosis of patients treated with Poteligeo as well as the monitoring required for adverse events and long-term efficacy, approval requires Poteligeo to be prescribed by, or in consultation with, a physician who specializes in the condition being treated.

**Automation:** None.

### RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Poteligeo is recommended in those who meet one of the following criteria:

#### FDA-Approved Indication

1. **Mycosis Fungoides/Sezary Syndrome.** Approve for 1 year if Poteligeo is prescribed by or in consultation with an oncologist or dermatologist.

#### Other Uses With Supportive Evidence

2. **Adult T-cell Leukemia/Lymphoma.** Approve for 1 year if the patient meets BOTH of the following (A and B):
  - A) Patient has relapsed or refractory disease; AND
  - B) Poteligeo is prescribed by or in consultation with an oncologist.

### CONDITIONS NOT RECOMMENDED FOR APPROVAL

09/04/2024

© 2024. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

Coverage of Poteligeo is not recommended in the following situations:

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

## REFERENCES

1. Poteligeo® injection [prescribing information]. Bedminster, NJ: Kyowa Kirin; March 2023.
2. NCCN Primary Cutaneous Lymphomas Clinical Practice Guidelines in Oncology (version 3.2024 – August 22, 2024). © 2024 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on August 30, 2024.
3. NCCN Drugs & Biologics Compendium. © 2024 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on August 30, 2024. Search terms: mogamulizumab-kpkc.
4. NCCN T-Cell Lymphomas Clinical Practice Guidelines in Oncology (version 4.2024 – May 28, 2024). © 2024 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on August 30, 2024.